The EVP of Translational Sciences and Chief Quality Of of Ultragenyx Pharmaceutical (NASDAQ: RARE) is Selling Shares

Yesterday, the EVP of Translational Sciences and Chief Quality Of of Ultragenyx Pharmaceutical (RAREResearch Report), John Richard Pinion, sold shares of RARE for $23.06K.

Following John Richard Pinion’s last RARE Sell transaction on March 03, 2020, the stock climbed by 39.5%. In addition to John Richard Pinion, 10 other RARE executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Ultragenyx Pharmaceutical’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $61.71 million and quarterly net profit of $25.32 million. In comparison, last year the company earned revenue of $24.15 million and had a GAAP net loss of $99.17 million. The company has a one-year high of $99.25 and a one-year low of $31.99. Currently, Ultragenyx Pharmaceutical has an average volume of 487.99K.

Based on 7 analyst ratings, the analyst consensus is Strong Buy with an average price target of $90.57, reflecting a 1.7% upside.

The insider sentiment on Ultragenyx Pharmaceutical has been negative according to 101 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.